An authorized generic version of Evzio (naloxone HCl injection) is expected to be available next year at a price of $178 per carton, according to Kaléo, the manufacturer of Evzio.
Evzio is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present.
In addition to the new authorized generic, Evzio is now available at $178 per carton (2 auto-injectors per carton) for government agencies, first responders, health departments, and other qualifying groups when they purchase directly from kaléo or authorized distributors. “In recognition of the growing need for take-home naloxone and by taking these steps, we can help provide even greater access to patients, care partners, clinicians, first responders and other key members of the community dedicated to tackling this tragic crisis,” said Omar Khalil, kaléo’s General Manager for Addiction and Neurology.
The authorized generic will be available in mid 2019 in the same formulation and design as the branded product (2mg/0.4mL solution in a prefilled auto-injector). The product incorporates audio and visual cues to help the user through the injection process.
For more information visit Kaleo.com.
This article originally appeared on MPR